Leaving This Website

You are leaving this page. This link will take you to a website where our Terms of Use do not apply. EMD Serono, a business of Merck KGaA, Darmstadt, Germany has no control over the contents and policies of these sites or resources, and accepts no responsibility for your use of them.

Please Confirm

This website is an information resource intended only for Healthcare Professionals from U.S., Puerto Rico and Canada who are interested in information on Clinical Research and EMD Serono sponsored clinical trials.++

By clicking "I am a healthcare professional" you are declaring and confirming that you are a Healthcare Professional inside the U.S., Puerto Rico and Canada and have read and understood this disclaimer.

Precision Medicine 

What is precision medicine?

  • Precision medicine is "an emerging approach for disease treatment and prevention that takes into account individual variability in genes, environment, and lifestyle for each person"1
  •  In oncology, precision medicine is further defined as “the use of therapeutics that are expected to confer benefit to a subset of patients whose cancer displays specific molecular or cellular features (most commonly genomic changes and changes in gene or protein expression patterns)”2
  •  Guidelines now recommend testing for several molecular alterations in patients with non-small cell lung cancer (NSCLC); including EGFR, ALK, ROS1, KRAS, BRAF, NTRK, RET, ERBB2 and MET alterations, which can be used to guide treatment decisions3

What are MET alterations?

  • MET is crucial for normal biological processes; including embryonic and organ development, as well as tissue repair and wound healing4,5
  • Alterations to the MET gene can cause aberrant activation of the MET signaling pathway, which can drive tumor growth through increased cell proliferation, survival, invasion and metastasis4,5
  • The most common types of MET gene alterations in NSCLC, include MET exon 14 skipping and MET amplification4,5 
  • These MET alterations can be identified via tissue or liquid biopsy6–8

MET dysregulation and rationale for targeting in NSCLC

Tepotinib is under clinical investigation in several countries of the world. Safety and efficacy of tepotinib have to be investigated following the respective local regulations and laws. There is no guarantee that tepotinib will be approved in the sought-after indication by the competent health authority in your country.

What is tepotinib?

  • Tepotinib is an investigational oral MET inhibitor that is designed to inhibit the oncogenic MET receptor signaling caused by MET alterations, including both METex14 skipping alterations and MET amplifications, or MET protein overexpression9
  • By selectively inhibiting MET signaling, tepotinib treatment aims to prevent tumor cell proliferation, survival and migration9
  • Tepotinib is currently being investigated in clinical trials for the treatment of patients with NSCLC with MET exon 14 skipping or MET amplification6–8




1. National Institutes of Health, US National Library of Medicine. What is precision medicine? Available at https://ghr.nlm.nih.gov/primer/precisionmedicine/definition. Accessed May 12, 2020.

2. Yates LR et al. Ann Oncol 2018;29:30-35.

3. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology, Non-Small Cell Lung Cancer (v3.2020). Available at: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Accessed May 12, 2020.

4. Drilon A et al. J Thorac Oncol. 2017;12(1):15–26

5. Wu YL et al. Cancer Treat Rev. 2017;61:70–81

6. Paik PK et al. J Clin Oncol. 2019;37 (15_suppl):9005

7. Salgia R et al. Cancer Treat Rev. 2020;87:102002

8. Yang JCH et al. Ann Oncol. 2019; 30(suppl_9):ix181

9. Bladt F et al. Clin Cancer Res. 2013;19(11):2941–2951